Daily Ards Research Analysis
Three clinical studies highlight actionable levers across the ARDS care continuum: an ECMO anticoagulation strategy (bivalirudin plus aspirin) was associated with longer oxygenator lifespan in COVID-19 ARDS; a hospital-wide trauma care redesign reduced in-hospital mortality and ARDS complications; and COVID-19 with active tuberculosis showed notable ICU and mortality risks with identifiable predictors.
Summary
Three clinical studies highlight actionable levers across the ARDS care continuum: an ECMO anticoagulation strategy (bivalirudin plus aspirin) was associated with longer oxygenator lifespan in COVID-19 ARDS; a hospital-wide trauma care redesign reduced in-hospital mortality and ARDS complications; and COVID-19 with active tuberculosis showed notable ICU and mortality risks with identifiable predictors.
Research Themes
- Anticoagulation strategies to extend ECMO oxygenator lifespan in ARDS
- Systems engineering in emergency care reducing ARDS complications and mortality
- Outcomes and risk factors in COVID-19 with active tuberculosis including ARDS
Selected Articles
1. Prolonged Use of Extracorporeal Membrane Oxygenators for COVID-19-Associated Acute Respiratory Distress Syndrome: A Retrospective Analysis.
In 70 adults on ECMO for COVID-19 ARDS (≥7 days), 68.6% required no oxygenator exchange; out-of-target aPTT exposure correlated with shorter oxygenator lifespan. The data suggest that bivalirudin plus aspirin may optimize anticoagulation and reduce oxygenator exchange frequency.
Impact: Guides anticoagulation to preserve ECMO circuit integrity, a key determinant of resource use and complications in prolonged ECMO runs.
Clinical Implications: Maintain tight aPTT control and consider bivalirudin plus aspirin to potentially extend oxygenator life and reduce circuit thrombosis; prospective trials are needed before protocol changes.
Key Findings
- Among 70 COVID-19 ARDS ECMO patients (≥7 days), 48 (68.6%) required no oxygenator replacement over a mean 34.9 ± 23.5 days (range 7–104).
- Twenty-two patients (31.4%) needed 35 oxygenator replacements during a mean ECMO duration of 56.9 ± 22.8 days (range 19–102).
- Higher proportions of out-of-target aPTT were associated with shorter oxygenator lifespan, despite similar mean aPTT between groups.
- An anticoagulation strategy with bivalirudin plus aspirin may enable more effective oxygenator utilization.
Methodological Strengths
- Clearly defined inclusion (ECMO ≥7 days) and standardized aPTT targets (45–60 s).
- Objective endpoint (oxygenator replacement due to circuit thrombosis) and continuous anticoagulation monitoring.
Limitations
- Retrospective single-center design with potential confounding and selection bias.
- Anticoagulation regimen assignments and aspirin use may not be randomized; causality cannot be inferred.
Future Directions: Conduct multicenter prospective studies or RCTs comparing anticoagulation regimens (including bivalirudin ± antiplatelet) with standardized aPTT targets and device outcomes.
Whether an anticoagulation strategy combining bivalirudin and aspirin during extracorporeal membrane oxygenation (ECMO) would prolong oxygenator use is unknown. No clear data exist on oxygenator life span during prolonged ECMO use. We evaluated 70 adult patients who received ECMO due to coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome for at least 7 days and who required no or at least one ECMO oxygenator replacement due to ECMO-circuit thrombosis. Anticoagulation parameters mainly included activated partial thromboplastin time (aPTT), with monitoring of international normalized ratio and platelet count. The main target aPTT was 45-60 seconds. The indication for oxygenator replacement was ECMO-circuit thrombosis. The mean ECMO duration was 41.8 ± 25.3 days. No oxygenator replacement was required in 48 patients (68.6%) during a mean of 34.9 ± 23.5 ECMO days (range 7-104). Twenty-two patients (31.4%) required 35 oxygenator replacements throughout a mean ECMO duration of 56.9 ± 22.8 days (range 19-102). The mean aPTT was similar throughout ECMO in the two groups. A higher percentage of out-of-target aPTT was associated with a shorter duration of oxygenator use. Bivalirudin plus aspirin may prove to be a more appropriate anticoagulation strategy during ECMO, resulting in more effective utilization of ECMO oxygenators.
2. The effect of a new in-hospital trauma care model on the outcomes of severely injured trauma patients in the emergency department: a retrospective observational study in China.
A hospital-wide trauma care redesign improved time-critical processes, increased early resuscitation success, and reduced mortality and ARDS/DIC complications among 366 severely injured patients. Findings support systems-level interventions to mitigate preventable secondary lung injury and organ failure.
Impact: Demonstrates that organizational redesign can halve mortality and ARDS/DIC complications, offering a scalable pathway for quality improvement in resource-constrained settings.
Clinical Implications: Adopting structured trauma pathways with rapid vascular access, airway, imaging, and early decision-making can reduce ARDS incidence and mortality; implementation science strategies are warranted.
Key Findings
- Time to key interventions was significantly reduced (e.g., circulation access 15.66→9.44 min; airway 36.90→23.91 min; whole-body CT 57.18→42.17 min).
- Bedside FAST completion improved (53.1%→92.8%) and first-hour resuscitation success increased (≈70.9%→85.0%).
- In-hospital mortality decreased (12.1%→5.9%) and DIC/ARDS complications declined (23.9%→9.2%), all statistically significant.
Methodological Strengths
- Large single-center cohort (n=366) with standardized quality indicators and comparable baseline characteristics.
- Multiple process and outcome measures demonstrating coherent effect across the care pathway.
Limitations
- Retrospective pre–post design susceptible to temporal and unmeasured confounding.
- Single-center experience may limit generalizability; detailed ARDS diagnostic criteria not elaborated.
Future Directions: Prospective multicenter implementation studies with fidelity monitoring to confirm mortality and ARDS reductions and identify key components driving benefit.
BACKGROUND: The mortality and disability rates among severely injured trauma patients are very high. This study aimed to investigate whether a new in-hospital trauma care model can improve emergency care efficiency and enhance the prognosis of severely injured trauma patients. METHODS: This retrospective observational study included 366 severely injured trauma patients (ISS ≥ 16) who were admitted to the emergency department of a tertiary hospital between 2023 and 2024. Based on the emergency care model used, patients were divided into the traditional model group (n = 213) from January to April 2023 and the new model group (n = 153) from January to April 2024. The general clinical data, prognosis information, as well as seven emergency quality control indicators for both groups were collected and analyzed. RESULTS: The study included 270 male patients (73.8%) and 96 female patients (26.2%), with a mean age of 56 (44, 69) years. No significant differences were found between the two groups regarding gender, age, time since injury, mechanism of injury, and vital signs upon admission (P > 0.05). The new model group had significantly shorter times for establishing effective circulation access (15.66 ± 3.36 vs. 9.44 ± 3.18 min), establishing an artificial airway (36.90 ± 12.23 vs. 23.91 ± 9.07 min), preparing blood transfusion (48.84 ± 5.73 vs. 31.0 ± 64.67 min), completing whole-body CT scans (57.18 ± 8.26 vs. 42.17 ± 7.28 min), and developing a definitive treatment plan (77.45 ± 6.26 vs. 56.50 ± 6.35 min) compared to the traditional model group. Additionally, the new model group had a significantly higher rate of bedside FAST completion (92.8% vs. 53.1%) and a higher success rate of resuscitation within the first hour (70.9% vs. 85.0%) than the traditional model group. Regarding prognosis, the new model group had a lower overall in-hospital mortality rate (12.1% vs. 5.9%) and a lower incidence of complications such as DIC and ARDS (23.9% vs. 9.2%, all P < 0.05). CONCLUSION: The new in-hospital trauma care model significantly enhanced the in-hospital emergency care efficiency, reduced in-hospital mortality, and decreased the incidence of complications for severely injured patients, which may serve as a useful reference for developing countries in similar settings. CLINICAL TRIAL NUMBER: Not applicable.
3. Clinical outcomes of patients with coronavirus disease 2019 and active tuberculosis co-infection in Beijing China: A retrospective single-center descriptive study.
Among 102 patients with COVID-19 and active TB, ARDS occurred in 11.8%, ICU admission in 15.7%, and in-hospital mortality was 9.8%. Elevated proinflammatory cytokines were common, and respiratory failure, pulmonary fungal infection, and need for ventilation/oxygen therapy predicted ICU admission.
Impact: Defines clinical risks and outcomes in COVID-19–TB coinfection, informing triage and monitoring strategies where TB burden remains high.
Clinical Implications: Early identification of coinfected patients at risk (respiratory failure, fungal coinfection) and proactive management may reduce ICU transfers and mortality; integrate TB care with COVID-19 pathways.
Key Findings
- In 102 COVID-19–TB patients, ARDS occurred in 11.76%, sepsis in 9.8%, and respiratory failure in 7.84%.
- ICU admission was 15.69% and in-hospital mortality 9.80%.
- Elevated IFN-γ, IL-1β, IP-10, and MCP-1 levels were observed.
- Respiratory failure, pulmonary fungal infection, and need for ventilation/oxygen therapy independently predicted ICU admission.
Methodological Strengths
- WHO-based severity grading and multivariable logistic regression for ICU risk factors.
- Cohort of 102 patients with detailed clinical, imaging, and cytokine profiling.
Limitations
- Single-center retrospective design over a short enrollment window limits generalizability.
- No matched control group and potential unmeasured confounding.
Future Directions: Prospective multicenter cohorts to validate predictors, characterize longitudinal lung injury (including ARDS progression), and assess integrated TB–COVID care pathways.
BACKGROUND: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) co-infection (COVID-19-TB) has the potential to exacerbate lung damage; however, information about the clinical features of COVID-19-TB is limited. This study aims to clarify the clinical characteristics and outcomes of patients with COVID-19-TB. METHODS: In this single-center retrospective study, the clinical features and outcomes of patients with COVID-19 with active TB who were admitted to Beijing Chest Hospital, Beijing, China, from 1 December 2022 to 18 January 2023 were collected. The severity of COVID-19 and TB was graded according to guidelines from the World Health Organization. The relationships of demographic and clinical variables with intensive care unit (ICU) admission were evaluated using univariable and multivariable logistic regression models. RESULTS: Overall, 102 patients with COVID-19-TB were enrolled. The mean age was 54.5 years (range 36.5-70 years). The most common clinical manifestations were cough (68.63%), sputum production (53.92%), fever (51.96%), and ground-glass opacities (35.29%). Complications included acute respiratory distress syndrome (11.76%), sepsis (9.8%), and respiratory failure (7.84%). Patients with COVID-19-TB had high concentrations of various proinflammatory cytokines, including interferon-γ, interleukin-1β, interferon-γ-inducible protein 10 kD, and monocyte chemoattractant protein-1. Sixteen of the 102 patients with COVID-19-TB (15.69%) were admitted to the ICU, and 10 (9.80%) died during hospitalization. The significant risk factors for ICU admission were respiratory failure, pulmonary fungal infection, and ventilation and oxygen therapy. CONCLUSIONS: The mortality rate of COVID-19-TB was 9.80%. Several demographic and clinical characteristics were associated with adverse outcomes, indicating the importance of early recognition and treatment.